|
Toxic Epidermal Necrolysis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Allergic drug reactions are unpredictable; nevertheless, there is increased risk of drug hypersensitivity in (1) patients with cystic fibrosis who receive antibiotics; (2) patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) who receive trimethoprim-sulfamethoxazole or if human leukocyte antigen (HLA)-B*5701+ and receive the antiretroviral agent abacavir; (3) other genetically susceptible populations, e.g., Han-Chinese with HLA-B*1502+ who develop Stevens-Johnson syndrome and toxic epidermal necrolysis from carbamazepine, with HLA-B*5801+ who are at increased risk for such reactions from allopurinol, those with HLA-A*32:01 and receive vancomycin and develop drug reaction with eosinophilia and systemic symptoms syndrome; and (4) patients with a history of compatible allergic reactions to the same medication, similar class, or potentially unrelated medication.
|
31690398 |
2019 |
|
Toxic Epidermal Necrolysis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
HLA haplotype analyses indicated that HLA-A*02:06:01 is primarily associated with susceptibility to CM-SJS/TEN with SOCs.
|
31700100 |
2019 |
|
Toxic Epidermal Necrolysis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The variant allele HLA-A*31:01 is associated with greater risk of maculopapular exanthema, drug reaction with eosinophilia and systemic symptoms, and SJS/TEN in patients treated with carbamazepine.
|
29392710 |
2018 |
|
Toxic Epidermal Necrolysis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We focused on 80 Indian patients with SJS/TEN with severe ocular complications (SOC) and investigated the association of alleles at HLA -A, HLA-B and HLA-C loci; the controls were 50 healthy Indian volunteers.
|
29162886 |
2017 |
|
Toxic Epidermal Necrolysis
|
0.400 |
Biomarker
|
disease |
BEFREE |
SJS and TEN were found to be significantly associated with HLA-A*33:03 and HLA-C*03:02 alleles in both groups of studies with matched controls and population controls.
|
28438823 |
2017 |
|
Toxic Epidermal Necrolysis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In Japanese individuals, HLA-A*02:06, HLA-A*02:07, HLA-A*31:01 and HLA-B*51:01 may be linked to higher risks of TEN.
|
27400826 |
2017 |
|
Toxic Epidermal Necrolysis
|
0.400 |
Biomarker
|
disease |
BEFREE |
HLA-A*31: 01 and HLA-B*15:02 association with Stevens-Johnson syndrome and toxic epidermal necrolysis to carbamazepine in a multiethnic Malaysian population.
|
28570299 |
2017 |
|
Toxic Epidermal Necrolysis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Associations between HLA and carbamazepine hypersensitivity reactions demonstrate both ethnicity and phenotype specificity; with HLA-B*15:02 associated with Stevens-Johnson syndrome and toxic epidermal necrolysis in South East Asian patients only whilst HLA-A*31:01 is associated with all phenotypes of hypersensitivity in multiple ethnicities.
|
24777842 |
2015 |
|
Toxic Epidermal Necrolysis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover, HLA-A*02:06 with TLR3 polymorphisms and HLA-A*02:06 with EP3 polymorphisms exerted additive effects in SJS/TEN with SOCs.
|
26448174 |
2015 |
|
Toxic Epidermal Necrolysis
|
0.400 |
Biomarker
|
disease |
BEFREE |
HLA-A*02:06 was strongly associated with CM-SJS/TEN with SOC and AR-SJS/TEN with SOC.
|
24781922 |
2014 |
|
Toxic Epidermal Necrolysis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increasing studies reported genetic susceptibility to drug hypersensitivity reactions, as exemplified by the HLA-A*31:01 and HLA-B*15:02 association with carbamazepine (CBZ)-induced hypersensitivity reactions, such as maculopapular exanthema (MPE), drug rash with eosinophilia and systemic symptoms (DRESS), and Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN).
|
24268988 |
2014 |
|
Toxic Epidermal Necrolysis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found that HLA-B*44:03 was significantly associated with CM-SJS/TEN with SOC in the Indian and Brazilian but not the Korean population, and that HLA-A*02:06 might be weakly associated in the Korean- but not the Indian and Brazilian population.
|
25099678 |
2014 |
|
Toxic Epidermal Necrolysis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Carrier frequencies of HLA-A*02:07 in patients with zonisamide-induced SJS/TEN and in the general Japanese population were 41.7 and 6.81%, respectively.
|
24236482 |
2013 |
|
Toxic Epidermal Necrolysis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found that HLA-A*0206 exhibited a high odds ratio for SJS/TEN (carrier frequency: OR = 5.1; gene frequency: OR = 4.0) and that there was a strong association with TLR3 rs.5743312T/T SNP (OR = 7.4), TLR3 rs.3775296T/T SNP (OR = 5.8), TLR3 rs.6822014G/G SNP (OR = 4.8), TLR3 rs.3775290A/A SNP (OR = 2.9), TLR3 rs.7668666A/A SNP (OR = 2.7), TLR3 rs.4861699G/G SNP (OR = 2.3), and TLR3 rs.11732384G/G SNP (OR = 1.9).
|
22912896 |
2012 |
|
Toxic Epidermal Necrolysis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previous studies have demonstrated a strong association between carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (CBZ-induced SJS/TEN) and HLA-B*1502 in Chinese, and HLA-A*3101 but not HLA-B*1502 in Caucasians and Japanese.
|
22348435 |
2012 |
|
Toxic Epidermal Necrolysis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The frequencies of HLA-A*33:03 as well as C*03:02 and C*08:01 were significantly higher in SJS/TEN patient subgroup showing allopurinol drug-induced severe cutaneous adverse reactions (SCAR) as compared to controls (28.6% vs 0%, P=0.00002, Pc=0.0011; 28.6% vs 0%, P=0.00002, Pc=0.001; 28.6% vs 0%, P=0.00002, Pc=0.001, respectively).
|
21545408 |
2011 |
|
Toxic Epidermal Necrolysis
|
0.400 |
Biomarker
|
disease |
BEFREE |
HLA-A*0206 was strongly associated with SJS/TEN.HLA-A*1101 was inversely associated.
|
18385790 |
2008 |
|
Toxic Epidermal Necrolysis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We clarified that HLA-A*0206 is strongly associated with SJS/TEN with ocular complications in the Japanese.
|
17258541 |
2007 |
|
Toxic Epidermal Necrolysis
|
0.400 |
Biomarker
|
disease |
CTD_human |
|
|
|